SMAD2 and cancer: Interestingly, while TGFβs and Activins activate the same Smad pathway (Smad2/3), TGFβs autocrine mechanisms have been much more frequently described to be implicated in cancer progression than Activins (Chen et al, 2002; Wakefield & Hill, 2013), highlighting a singularity of Group 3 MBs.